Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia

US intergroup trial E2997

Ian W. Flinn, Donna S. Neuberg, Michael R. Grever, Gordon W. Dewald, John M. Bennett, Elisabeth M. Paietta, Mohamad A. Hussein, Frederick R. Appelbaum, Richard A. Larson, Dennis F. Moore, Martin S. Tallman

Research output: Contribution to journalArticle

340 Citations (Scopus)

Abstract

Purpose: The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by increased toxicity compared with fludarabine alone. E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL. Patients and Methods: Symptomatic, previously untreated patients with CLL were randomly assigned to receive either fludarabine 25 mg/m2 intravenously (IV) days 1 through 5 or cyclophosphamide 600 mg/m2 IV day 1 and fludarabine 20 mg/m 2 IV days 1 through 5. These cycles were repeated every 28 days for a maximum of six cycles. Results: A total of 278 patients were randomly assigned in this Intergroup study. Treatment with fludarabine and cyclophosphamide was associated with a significantly higher complete response (CR) rate (23.4% v 4.6%; P < .001) and a higher overall response (OR) rate (74.3% v 59.5%, P = .013) than treatment with fludarabine as a single agent. Progression-free survival (PFS) was also superior in patients treated with fludarabine and cyclophosphamide than those treated with fludarabine (31.6 v 19.2 months, P < .0001). Fludarabine and cyclophosphamide caused additional hematologic toxicity, including more severe thrombocytopenia (P = .046), but it did not increase the number of severe infections (P = .812). Conclusion: Fludarabine and cyclophosphamide produced an increase in OR and CR, and it improved PFS in patients with previously untreated CLL compared with fludarabine alone and was not associated with an increase in infectious toxicity.

Original languageEnglish (US)
Pages (from-to)793-798
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number7
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
fludarabine
Disease-Free Survival
Thrombocytopenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia : US intergroup trial E2997. / Flinn, Ian W.; Neuberg, Donna S.; Grever, Michael R.; Dewald, Gordon W.; Bennett, John M.; Paietta, Elisabeth M.; Hussein, Mohamad A.; Appelbaum, Frederick R.; Larson, Richard A.; Moore, Dennis F.; Tallman, Martin S.

In: Journal of Clinical Oncology, Vol. 25, No. 7, 01.03.2007, p. 793-798.

Research output: Contribution to journalArticle

Flinn, Ian W. ; Neuberg, Donna S. ; Grever, Michael R. ; Dewald, Gordon W. ; Bennett, John M. ; Paietta, Elisabeth M. ; Hussein, Mohamad A. ; Appelbaum, Frederick R. ; Larson, Richard A. ; Moore, Dennis F. ; Tallman, Martin S. / Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia : US intergroup trial E2997. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 7. pp. 793-798.
@article{a20ef2f8c47a498f9d9ec8c7c680d2a4,
title = "Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997",
abstract = "Purpose: The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by increased toxicity compared with fludarabine alone. E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL. Patients and Methods: Symptomatic, previously untreated patients with CLL were randomly assigned to receive either fludarabine 25 mg/m2 intravenously (IV) days 1 through 5 or cyclophosphamide 600 mg/m2 IV day 1 and fludarabine 20 mg/m 2 IV days 1 through 5. These cycles were repeated every 28 days for a maximum of six cycles. Results: A total of 278 patients were randomly assigned in this Intergroup study. Treatment with fludarabine and cyclophosphamide was associated with a significantly higher complete response (CR) rate (23.4{\%} v 4.6{\%}; P < .001) and a higher overall response (OR) rate (74.3{\%} v 59.5{\%}, P = .013) than treatment with fludarabine as a single agent. Progression-free survival (PFS) was also superior in patients treated with fludarabine and cyclophosphamide than those treated with fludarabine (31.6 v 19.2 months, P < .0001). Fludarabine and cyclophosphamide caused additional hematologic toxicity, including more severe thrombocytopenia (P = .046), but it did not increase the number of severe infections (P = .812). Conclusion: Fludarabine and cyclophosphamide produced an increase in OR and CR, and it improved PFS in patients with previously untreated CLL compared with fludarabine alone and was not associated with an increase in infectious toxicity.",
author = "Flinn, {Ian W.} and Neuberg, {Donna S.} and Grever, {Michael R.} and Dewald, {Gordon W.} and Bennett, {John M.} and Paietta, {Elisabeth M.} and Hussein, {Mohamad A.} and Appelbaum, {Frederick R.} and Larson, {Richard A.} and Moore, {Dennis F.} and Tallman, {Martin S.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1200/JCO.2006.08.0762",
language = "English (US)",
volume = "25",
pages = "793--798",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia

T2 - US intergroup trial E2997

AU - Flinn, Ian W.

AU - Neuberg, Donna S.

AU - Grever, Michael R.

AU - Dewald, Gordon W.

AU - Bennett, John M.

AU - Paietta, Elisabeth M.

AU - Hussein, Mohamad A.

AU - Appelbaum, Frederick R.

AU - Larson, Richard A.

AU - Moore, Dennis F.

AU - Tallman, Martin S.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Purpose: The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by increased toxicity compared with fludarabine alone. E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL. Patients and Methods: Symptomatic, previously untreated patients with CLL were randomly assigned to receive either fludarabine 25 mg/m2 intravenously (IV) days 1 through 5 or cyclophosphamide 600 mg/m2 IV day 1 and fludarabine 20 mg/m 2 IV days 1 through 5. These cycles were repeated every 28 days for a maximum of six cycles. Results: A total of 278 patients were randomly assigned in this Intergroup study. Treatment with fludarabine and cyclophosphamide was associated with a significantly higher complete response (CR) rate (23.4% v 4.6%; P < .001) and a higher overall response (OR) rate (74.3% v 59.5%, P = .013) than treatment with fludarabine as a single agent. Progression-free survival (PFS) was also superior in patients treated with fludarabine and cyclophosphamide than those treated with fludarabine (31.6 v 19.2 months, P < .0001). Fludarabine and cyclophosphamide caused additional hematologic toxicity, including more severe thrombocytopenia (P = .046), but it did not increase the number of severe infections (P = .812). Conclusion: Fludarabine and cyclophosphamide produced an increase in OR and CR, and it improved PFS in patients with previously untreated CLL compared with fludarabine alone and was not associated with an increase in infectious toxicity.

AB - Purpose: The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be accompanied by increased toxicity compared with fludarabine alone. E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL. Patients and Methods: Symptomatic, previously untreated patients with CLL were randomly assigned to receive either fludarabine 25 mg/m2 intravenously (IV) days 1 through 5 or cyclophosphamide 600 mg/m2 IV day 1 and fludarabine 20 mg/m 2 IV days 1 through 5. These cycles were repeated every 28 days for a maximum of six cycles. Results: A total of 278 patients were randomly assigned in this Intergroup study. Treatment with fludarabine and cyclophosphamide was associated with a significantly higher complete response (CR) rate (23.4% v 4.6%; P < .001) and a higher overall response (OR) rate (74.3% v 59.5%, P = .013) than treatment with fludarabine as a single agent. Progression-free survival (PFS) was also superior in patients treated with fludarabine and cyclophosphamide than those treated with fludarabine (31.6 v 19.2 months, P < .0001). Fludarabine and cyclophosphamide caused additional hematologic toxicity, including more severe thrombocytopenia (P = .046), but it did not increase the number of severe infections (P = .812). Conclusion: Fludarabine and cyclophosphamide produced an increase in OR and CR, and it improved PFS in patients with previously untreated CLL compared with fludarabine alone and was not associated with an increase in infectious toxicity.

UR - http://www.scopus.com/inward/record.url?scp=33947541773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947541773&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.08.0762

DO - 10.1200/JCO.2006.08.0762

M3 - Article

VL - 25

SP - 793

EP - 798

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -